208934-35-4

Basic information

• Product Name: 4-(Tributylstannyl)-1-tritylimidazole
• Synonyms: 4-(Tributylstannyl)-1-tritylimidazole;4-(tributylstannanyl)-1-trityl-1H-iMidazole;4-(Tributylstannyl)-1-trityl-1H-imidazole
• CAS NO: 208934-35-4
• Molecular Formula: C₃₄H₄₄N₂Sn
• Molecular Weight: 599.446
• Product Categories: Stannanes;organic tin
• Mol File: 208934-35-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 611.643°C at 760 mmHg
• Flash Point: 323.71°C
• Appearance: /
• Vapor Pressure: 0mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 6.32±0.70(Predicted)
• CAS DataBase Reference: 4-(Tributylstannyl)-1-tritylimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Tributylstannyl)-1-tritylimidazole(208934-35-4)
• EPA Substance Registry System: 4-(Tributylstannyl)-1-tritylimidazole(208934-35-4)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 208934-35-4(Hazardous Substances Data)

Usage

General Description

4-(Tributylstannyl)-1-tritylimidazole is a complex organic chemical compound used in various types of chemical research and experiment. It contains elements like Carbon (C), Hydrogen (H), Nitrogen (N), Tin (Sn), and belongs to the class of compounds known as organotin compounds. Organotin compounds are a sub-class of organometallic compounds that contain at least one bond between a carbon atom and a tin atom. Among its significant roles, it is often utilized as a reagent in making compounds through various types of synthesis reactions. It is also known for its properties as a potential biological, health, and environmental hazard due to its toxicity. It should therefore be handled with caution according to established safety protocols in the scientific laboratory setting.

InChI:InChI=1/C22H17N2.3C4H9.Sn/c1-4-10-19(11-5-1)22(24-17-16-23-18-24,20-12-6-2-7-13-20)21-14-8-3-9-15-21;3*1-3-4-2;/h1-15,17-18H;3*1,3-4H2,2H3;/rC34H44N2Sn/c1-4-7-25-37(26-8-5-2,27-9-6-3)33-28-36(29-35-33)34(30-19-13-10-14-20-30,31-21-15-11-16-22-31)32-23-17-12-18-24-32/h10-24,28-29H,4-9,25-27H2,1-3H3

Upstream product

• 96797-15-8 N-trityl-4⁽⁵⁾-iodoimidazole 
• 76-83-5 trityl chloride 
• 1461-22-9 tributyltin chloride 
• 925-90-6 ethylmagnesium bromide 
• 920-39-8 isopropylmagnesium bromide 

Downstream Products

• 862500-53-6 2-(1-trityl-1H-imidazol-4-yl)-thiazole-5-carboxylic acid methyl ester 
• 179759-77-4 hydroxy-(1-trityl-1H-imidazol-4-yl)acetic acid ethyl ester 

Relevant articles and documents

COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF

The present invention provides KDM5 inhibitor. The compound disclosed herein represented by the general formula (Z): wherein all symbols have the same meanings as the definitions described in the specification; or a salt thereof is useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, or Alzheimer's disease and the like.

FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF

This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.

THIAZOLYL-HYDROXAMIC ACIDS AND THIADIAZOLYL-HYDROXAMIC ACIDS, AND USE THEREOF FOR TREATING DISEASES ASSOCIATED WITH HISTONE DEACETYLASE ENZYMATIC ACTIVITY

A compound of formula: (I) in which A represents optionally substituted monocyclic heteroaryl or phenyl; B represents optionally substituted heteroaryl, aryl, aryl-fused-heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl or aryl-fused-cycloalkyl, or B represents H when L represents a single bond; L represents a single bond, alkylene, (CH2)nX(CH2)m, (CH2)nX(CH2)pY(CH2)m; Q represents N or CR2; T represents N or CR2, provided that Q and T do not both represent CR2 simultaneously; X represents -O-, -NR3-, -CO-, -SO2-, -NR3C0-, -NR3SO2-, -CONR3-, -SO2NR3-, -NR1CONR1-; Y represents -NR3- or -O-; Rl represents H or alkyl; R2 represents hydrogen, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, CN; R3 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, or alkyl substituted by -OR4, -NR5R6, -NR6COR7, -NR6SO2R7, -CONR5R6 or -SO2NR5R6; R4 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl or cycloalkyl; R5 represents H or alkyl; R6 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl or cycloalkyl or NR5R6 represents a cyclic amine; R7 represents alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl; n represents 0-3; m represents 0-3; p represents 1-3; and corresponding N-oxides, pharmaceutically acceptable salts, solvates and prodrugs thereof; and use to treat a disease in which inhibition of histone deacetylase can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease.